DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer.

@article{Eriksson2013DNAVC,
  title={DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer.},
  author={Fredrik Eriksson and Thomas H. T{\"o}tterman and A. Maltais and Pavel Pisa and Jeffrey Yachnin},
  journal={Vaccine},
  year={2013},
  volume={31 37},
  pages={3843-8}
}
We tested safety, clinical efficacy and immunogenicity of a DNA vaccine coding for rhesus prostate specific antigen (PSA) delivered by intradermal injection and skin electroporation. Fifteen patients with biochemical relapse of prostate cancer without macroscopic disease participated in this phase I study. Patients were started on a 1 month course of androgen deprivation therapy (ADT) prior to treatment. Vaccine doses ranged from 50 to 1,600 μg. Study subjects received five vaccinations at four… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Trial Watch

View 5 Excerpts
Highly Influenced

A Review: Advances in Drug Delivery

Roonal Pritam Kataria, Jai Hind Collge
2015
View 1 Excerpt

Similar Papers

Loading similar papers…